Won Min Song, PhD
- ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
Research Topics:Alzheimer's Disease, Bioinformatics, Cancer Genetics, Genomics, Influenza Virus, Systems Biology
Won-Min Song, PhD, an Associate Professor in the Department of Genetics and Genomic Sciences, is a computational biologist versed in integrative multi-omics large-scale data analysis to identify disease mechanisms and therapeutic strategies by leveraging state-of-art network modeling. He has previously established the statistical mechanics of embedded networks in complex manifolds to translate network embedding as an effective modeling of complex real-world networks. This line of research extended to develop a new gene interaction network inference framework, Multiscale Embedded Gene co-Expression Network Analysis (MEGENA), to infer multi-scale interaction networks identifying from loose to compact modules of genes and their key drivers. MEGENA is recognized as a top 10% cited article from PLoS computational biology in 2015 (as of May, 2021). Based on these, data-driven gene regulatory network models integrating mutational, epigenetic, and genomic alterations/regulations have been constructed for complex genetic diseases such as cancers, influenza infection and asthma. These network models have informed key pathways and potential regulators exploited in the disease etiologies, thereby nominate therapeutic strategies targeting the exploited mechanisms. Currently, Dr. Song has extended the integrative network modeling framework to incorporate the cell-level molecular data from single-cell sequencing to dissect the interplay among diverse cells in the disease tissue micro-environment. A recent application to primary melanoma has revealed an intra-tumoral DNA repair pathway, regulated by ZNF180, as a key protumorigenic mechanism that underlies immune-melanoma cases and is associated with poor prognosis.
Lab website: https://labs.icahn.mssm.edu/songlab/
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Song did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.